scholarly journals Potential of natural astaxanthin in alleviating the risk of cytokine storm and improve health in COVID-19: A scoping review

2020 ◽  
Author(s):  
Jayanta Talukdar ◽  
Bhaskar Bhadra ◽  
Santanu Dasgupta ◽  
Vinod Nagle
Keyword(s):  
Clinical Trials ◽  
Inflammatory Cytokines ◽  
Scoping Review ◽  
Meta Analysis ◽  
Relevant Literature ◽  
Elevated Serum ◽  
Cytokine Release ◽  
Prisma Statement ◽  
Anti Oxidant ◽  
Anti Inflammatory

Abstract Background: Natural astaxanthin as a potent anti-oxidant and broad-spectrum anti-inflammatory bioactive molecule plays important role in modulating the immune response, speculated to be a potential supplement to alleviate cytokine release storm in COVID-19. Objective: Review of published literature to summarize the rationale for possible benefits of natural astaxanthin to support COVID-19 patients. Methods: Retrieved relevant literature from electronic databases including Google scholar, PubMed, Scopus, etc. and reviewed following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement. We adapted the article as scoping review. Results: Cytokine release syndrome (CRS) is reported as a common feature in COVID-19, which can lead to potentially fatal, hyper-inflammatory acute respiratory distress condition, diagnosed with elevated serum level of pro-inflammatory cytokines like IL-6, CRP, etc. that positively correlated with disease severity. Anti-inflammatory drug, like tocilizumab, etc. are under clinical trials as anti-CRS therapy. Astaxanthin can potentially alleviate CRS by regulating inflammatory cytokines by inhibiting the activities of NF-kB, TNF-α, JAK/STAT-3, etc. Available pre-clinical and clinical trials data support its excellent safety, and potential therapeutic and health benefits. Conclusions: Natural astaxanthin has tremendous potential as co-adjunctive supplement, desiring necessary clinical supports on its efficacy and beneficial against COVID-19.

scholarly journals Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials

2021 ◽  
Vol 93 ◽  
pp. 245-253 ◽  
Author(s):  
Joshua H. Cho ◽  
Saumya Bhutani ◽  
Carole H. Kim ◽  
Michael R. Irwin
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Meta Analysis ◽  
Anti Inflammatory

scholarly journals Macrophage Activation and Cytokine Release Syndrome in COVID-19: Current Updates and Analysis of Repurposed and Investigational Anti-Cytokine Drugs

Drug Research ◽  
2021 ◽  
Author(s):  
Ashif Iqubal ◽  
Farazul Hoda ◽  
Abul Kalam Najmi ◽  
Syed Ehtaishamul Haque
Keyword(s):  
Immune Response ◽  
Clinical Trials ◽  
Macrophage Activation ◽  
Fatality Rate ◽  
Cytokine Storm ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
Disease Condition ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

AbstractCoronavirus disease (COVID-19) emerged from Wuhan, has now become pandemic and the mortality rate is growing exponentially. Clinical complication and fatality rate is much higher for patients having co-morbid issues. Compromised immune response and hyper inflammation is hall mark of pathogenesis and major cause of mortality. Cytokine release syndrome (CRS) or cytokine storm is a term used to affiliate the situation of hyper inflammation and therefore use of anti-cytokine and anti-inflammatory drugs is used to take care of this situation. Looking into the clinical benefit of these anti-inflammatory drugs, many of them enter into clinical trials. However, understanding the immunopathology of COVID-19 is important otherwise, indiscriminate use of these drugs could be fetal as there exists a very fine line of difference between viral clearing cytokines and inflammatory cytokines. If any drug suppresses the viral clearing cytokines, it will worsen the situation and hence, the use of these drugs must be based on the clinical condition, viral load, co-existing disease condition and severity of the infection.

scholarly journals Mesenchymal stem cell therapy efficacy in COVID-19 patients: A systematic review and meta-analysis

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 956
Author(s):  
Andrianto Andrianto ◽  
Desak Ketut Sekar Cempaka Putri ◽  
Makhyan Jibril Al Farabi ◽  
Teuku Yusrizal ◽  
Hanestya Oky Hermawan
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Adverse Events ◽  
Inflammatory Cytokines ◽  
Meta Analysis ◽  
Group Versus ◽  
Mechanical Ventilators ◽  
Mesenchymal Stem Cell Therapy ◽  
Anti Inflammatory ◽  
Pro Inflammatory Cytokines

Objective: To evaluate mesenchymal stem cell (MSC) administration safety and efficacy in COVID-19 patients. Methods: We conducted a literature search on PubMed/MEDLINE, medRxiv, EBSCOhost/CINAHL, ProQuest, and Scopus with keywords adjusted to each search engine’s specifications on February 12, 2021. Interventional studies that reviewed MSC efficacy (mortality, hospitalization duration, need for mechanical ventilators, and inflammation markers) and/or safety (adverse events) in COVID-19 patients who were 18 years old or more were included in this study. Study eligibility, data extraction, and study quality assessment were conducted independently by each author. Results: A total of five studies of moderate to high quality with a total of 193 patients were included. One of the three randomized studies included did not apply blinding to either participants or medical professionals. Pooled OR (Odd Ratio) for mortality risk, adverse events incidence, and use of mechanical ventilators for patients on MSC therapy were 0.13 [95% CI: 0.02, 0.68], 0.91 [95% CI: 0.45, 1.86], and 0.42 [95% CI: 0.12, 1.47], respectively. Pooled mean difference for hospitalization duration in the MSC group versus the control was -3.54 [CI 95%: -4.68, -2.40] with 7% heterogeneity. All studies agreed that there was an increase of pro-inflammatory cytokines and a decrease of anti-inflammatory markers that were statistically different in the MSC group. Conclusion: Mesenchymal stem cell administration to COVID-19 patients is safe and effective in reducing mortality and hospitalization duration. Furthermore, a decrease of pro-inflammatory cytokines and an increase in anti-inflammatory cytokines were observed.

scholarly journals Various Phytochemicals Present in Maida Lakdi Litsea glutinosa (Lour) acts in the Management of Waja ul Mafasil (Arthritis) in a Clinical Trials

2021 ◽  
Vol 9 (11) ◽  
pp. 1-8
Author(s):  
Zaibunnisa Begum ◽  
Noor Banu Noorein ◽  
Shenaz Begum Modi
Keyword(s):  
Wound Healing ◽  
Clinical Trials ◽  
Joint Pain ◽  
Classical Text ◽  
Functional Activities ◽  
Anti Oxidant ◽  
Anti Inflammatory ◽  
Traditional Practitioners ◽  
Litsea Glutinosa ◽  
Anti Fungal

Litsea glutinosa (Lour) Maida Lakdi is an evergreen tree belonging to family Lauraceae it is a native to India.1,2,3 Ethinomedically the bark is used by the traditional practitioners as a demulcent, emollient and in the treatment of diarrhea and dysentery. According to ancient Unani classical text books by our ancient scholars which was used for mostly bony diseaseslike Fracture (kasar), Joint pain(Hudaar), gout(Naqras), sciatica(lrqun nasa), anti inflammatory(Muhalil e Auram), spacity of nerves(Tashannunj e Asab), nervine tonic(Muqavi e Asab)etc. and now a days further activities were found by various scientific studies paving a way for multi functional activities like Anti oxidant , analgesic anti inflammatory, anti pyretic, anti microbial, anti bacterial, anti fungal anti helminthic, wound healing, hepatoprotective, nephro protective, anti infertility,anti hyperglycemic and anti hyperlipidemic.

scholarly journals A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)

2018 ◽  
Vol 7 (10) ◽  
pp. 298 ◽  
Author(s):  
Qin Ng ◽  
Alex Soh ◽  
Wayren Loke ◽  
Nandini Venkatanarayanan ◽  
Donovan Lim ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Meta Analysis ◽  
Evidence Base ◽  
Biologically Active ◽  
Protective Effects ◽  
Severity Rating ◽  
Anti Oxidant ◽  
Anti Inflammatory ◽  
Irritable Bowel ◽  
Larger Sample

Irritable bowel syndrome (IBS) remains a prevalent and difficult-to-manage gastrointestinal condition. There is growing interest in the use of traditional medicine to manage IBS. In particular, curcumin, a biologically active phytochemical, has demonstrated anti-inflammatory and anti-oxidant properties and mucosal protective effects in rat models of colitis. This meta-analysis thus aimed to investigate the hypothesis that curcumin improves IBS symptoms. Using the keywords (curcumin OR turmeric OR Indian saffron OR diferuloylmethane OR curcuminoid) AND (irritable bowel syndrome OR IBS), a preliminary search on the PubMed, Medline, Embase, PsychINFO, Web of Science, and Google Scholar databases yielded 1080 papers published in English between 1 January 1988 and 1 May 2018. Five randomized, controlled trials were systematically reviewed and 3 were included in the final meta-analysis. Random-effects meta-analysis based on three studies and 326 patients found curcumin to have a beneficial albeit not statistically significant effect on IBS symptoms (pooled standardized mean difference from baseline IBS severity rating −0.466, 95% CI: −1.113 to 0.182, p = 0.158). This is the first meta-analysis to examine the use of curcumin in IBS. With its unique anti-oxidant and anti-inflammatory activities and ability to modulate gut microbiota, curcumin is a potentially useful addition to our armamentarium of agents for IBS. It also appears safe and well-tolerated, with no adverse events reported in the available trials. However, current findings are based on a considerably limited evidence base with marked heterogeneity. More robust clinical trials involving a standardized curcumin preparation and larger sample sizes should be encouraged.

scholarly journals Anti-Inflammatory Properties of Bellevalia saviczii Root Extract and Its Isolated Homoisoflavonoid (Dracol) Are Mediated by Modification on Calcium Signaling

Molecules ◽  
2019 ◽  
Vol 24 (18) ◽  
pp. 3376
Author(s):  
Monica Savio ◽  
Mohammed Farhad Ibrahim ◽  
Chiara Scarlata ◽  
Matteo Orgiu ◽  
Giuseppe Accardo ◽  
...  
Keyword(s):  
Medicinal Plant ◽  
Western Blot ◽  
Calcium Signaling ◽  
Inflammatory Cytokines ◽  
Nuclear Translocation ◽  
Herbal Remedy ◽  
Root Extract ◽  
Cytokine Release ◽  
Iraqi Kurdistan ◽  
Anti Inflammatory

Bellevalia saviczii is a medicinal plant used as anti-rheumatic and anti-inflammatory herbal remedy in Iraqi-Kurdistan. The aim of this study was to evaluate the anti-inflammatory activity of its extract and the isolated homoisoflavonoid (Dracol) by studying the Ca2+-dependent NF-kB pathway. Nuclear translocation of p65 NF-kB subunit, as parameter of NF-kB activation, was visualized in human leukemic monocytes by immunofluorescence and Western blot analyses, after cell treatment with B. saviczii root extract or Dracol followed by Lipopolysaccharide stimulation. In parallel, Ca2+ signals responsible for NF-kB activation and levels of inflammatory cytokines were investigated. LPS-induced p65 translocation was evident in monocytes and both treatments, in particular that with Dracol, were able to counteract this activation. Intracellular Ca2+ oscillations were halted and the cytokine release reduced. These results confirm the traditional anti-inflammatory efficacy of B. saviczii and identify one of the molecules in the extract which appears to be responsible of this action.

P.728 Anti-inflammatory cytokines in alcohol use disorder: a systematic review and meta-analysis

2019 ◽  
Vol 29 ◽  
pp. S489-S490
Author(s):  
H. Moura ◽  
F. Hansen ◽  
D. Silvello ◽  
F. Galland ◽  
F. Rebellato ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alcohol Use ◽  
Inflammatory Cytokines ◽  
Alcohol Use Disorder ◽  
Meta Analysis ◽  
Anti Inflammatory
Sign in / Sign up

Export Citation Format

Share Document